Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Konica Minolta’s Cancer Genomic Profiling System Approved in Japan
July 19, 2022
- Kyowa Kirin to Cease Development of Parkinson’s Hopeful KW-6356
July 19, 2022
- Japan Becoming Less Priority Market as Policy Changes Mar Predictability: MSD Exec
July 19, 2022
- Edirol Hits Chinese Market: Chugai
July 19, 2022
- Shionogi COVID Pill Shows Antiviral Activity Against BA.5
July 15, 2022
- Ultragenyx Takes Over Mepsevii Marketing Authorization in Japan
July 15, 2022
- Shingrix Shows Cost-Effectiveness in Japanese Older Adults: GSK Analysis
July 15, 2022
- Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
- Mochida to Discontinue Filgrastim Biosimilars Despite 50% Share
July 14, 2022
- Financially Weak Companies Will Go Under If Annual Price Cuts Continue: Sawai Chair
July 14, 2022
- BMS Japan on Track to Achieve Goals in Mid-Term Biz Plan: Chief
July 14, 2022
- Shionogi’s Four-Day Workweek Not So Popular Yet, but Side Job Plan Gaining Traction
July 13, 2022
- Healios to Provide iPSC Line to RxCell; License Talks with StemAxon Gets Underway
July 13, 2022
- Ex-Novartis Exec Jugo Tsumura Takes Reins at Ferring Japan
July 12, 2022
- Takeda Showcases Manufacturing Line for Cell Therapy Alofisel
July 11, 2022
- Organon Curbs Shipment of Fertility Med Ganirest in Japan
July 11, 2022
- As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
- Shipment Restrictions Continue for Vyndaqel, Vynmac: Pfizer Japan
July 8, 2022
- Japan Ethical Drug Sales Surge 6.2% in May: Crecon
July 8, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…